CLOs on the Move


 
We work at the intersection of biology, engineering, and design, developing technologies that emulate human biology. Our products are enabling a new era of precision medicine and the development of applications for personalized health. Our Human Emulation System, which uses Organs-on-Chips technology, is being used by industry, government, and academia to understand how different diseases, medicines, chemicals and foods affect human health. The system offers researchers a new standard for predicting human response — with greater precision and control than today`s cell culture or animal-based experimental methods. We are also leading a bold, new precision medicine initiative with our clinical ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Larry Weiss
Senior Vice President and Chief Legal Officer Profile
Monique Noel
General Counsel Profile

Similar Companies

arizonia infectious disease society

arizonia infectious disease society is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syan Biosciences

Syan Biosciences is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We`re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes.

MiRagen

miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.